Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

2.97
+0.04001.37%
Post-market: 2.92-0.0500-1.68%19:19 EST
Volume:156.73K
Turnover:472.68K
Market Cap:191.48M
PE:-5.03
High:3.10
Open:2.92
Low:2.90
Close:2.93
52wk High:7.13
52wk Low:1.12
Shares:64.47M
Float Shares:44.93M
Volume Ratio:1.07
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5905
EPS(LYR):-0.7575
ROE:-3727.94%
ROA:-87.09%
PB:-1.52
PE(LYR):-3.92

Loading ...

Galectin Therapeutics Halts Key NASH Cirrhosis Trial, Resetting Expectations for GALT

TIPRANKS
·
Yesterday

Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc

Reuters
·
Feb 10

Galectin Therapeutics Approves Retention Bonuses for Key Executives

TIPRANKS
·
Jan 22

Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers

Reuters
·
Jan 22

Top Galectin Therapeutics Insider Makes Notable Move With Company Stock

TIPRANKS
·
Jan 14

Marc Rubin Resigns from Galectin Therapeutics Board

Reuters
·
Jan 13

Galectin Therapeutics CFO Jack W. Callicutt Reports Disposal of Common Shares

Reuters
·
Jan 07

Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

Reuters
·
Jan 06

Galectin Therapeutics Director Kevin D. Freeman Reports Acquisition of Common Shares

Reuters
·
Dec 24, 2025

Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line

MT Newswires Live
·
Dec 19, 2025

BRIEF-Galectin Therapeutics Enters Line Of Credit Agreement

Reuters
·
Dec 19, 2025

BRIEF-Galectin Therapeutics Provides Regulatory Update Following FDA Written Response

Reuters
·
Dec 19, 2025

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit From Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

THOMSON REUTERS
·
Dec 19, 2025

Galectin Therapeutics Inc - to Pursue Follow-up Type C Meeting

THOMSON REUTERS
·
Dec 19, 2025

Galectin Therapeutics Inc - Enters Line of Credit Agreement - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Galectin Therapeutics Secures Additional $10 Million Line of Credit from Richard E. Uihlein

Reuters
·
Dec 19, 2025

10X Fund, L.P. Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 18, 2025

Galectin Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 17, 2025

Director Harold H. Shlevin Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 17, 2025